What’s your first line therapy for AS? Write below if you use something else! @RheumNow #ACR19

@RheumNow What is your primary pharmacotherapy for inflammatory-type erosive hand OA? #ACR19 @RheumNow Plenary II ABST1759/1760

FRAME study results: Romo increases MBBF on the Ec and Cn surfaces which stimulates bone formation during first 2 months of tx. https://t.co/qmbyt8w75Q #abs1874 #ACR19 @RheumNow https://t.co/FQIIU8kcsp

• Extensive Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment…

#acrbest @rheumnow #acr19 abstr#1901 VERY IMPT STUDY: 16,490 offspring of moms w/Rheum Dz: 105 on nonTNFi biologic or TOFA: NO ⬆️in utero SIE . Only 2 cases of SIE- 1 w/TOFA &1 w/ABT. Risk for SIE in utero For healthy 1.6% For TNFi 2.3% For nonTNFi + TOFA 2.1%

SLE has high work disability. Interestingly work disability was not high in some organ systems such as renal but mild GN or CRF may not be symptomatic. Fibromyalgia, low education, low SED and older age increase work disability ACR219 @RheumNow abstr 1578 https://t.co/DdHgluRPIV

DAPS study results suggest ALN use following DMAb cessation and BMD monitoring of patients transitioning from DMAb to ALN. https://t.co/xQHnevYyed abs #1875 #ACR19 @RheumNow https://t.co/DR13Cn6EYD

• Subject Characteristics and Changes in Bone Mineral Density After Transitioning…

Abstr#1898 #acr19 #acrbest @rheumnow Danish registry prospective RA pregnancy and offspring outcome n= 816 children born to parent w/RA- they performed a little worse in math grades 2,4,6, 8 compared to peers regardless of maternal seropositivity. No influence by paternal RA.

Study by Malik et al shows Magnetic Resonance Enterography (MRE) as a screening tool to detect Sacroilitis (SI) in Crohns Disease patients. Presence of SI on MRE in CD was found in 17% of patients. With back pain, this can lead to earlier diagnosis AxSpA #ACR19 @RheumNow

OP related fracture risk projected to increase to 33% by 2030. Medicare cohort from 2010- 2014 data review suggestions worsening fracture management. https://t.co/anG80uMjEV abs#1872 #ACR19 @RheumNow

• Worsening Trends in Osteoporosis Management in the Medicare Population: 2010-20…

#acr19 @RheumNow abstr#1899 #acrbest 71 preg pts sFlt-1, PlGF and VEGF possible biomarkers to disting b/t active SLE Nephritis During Pregnancy and Preeclampsia VEGF ⬆️ in LN PIGF ⬇️ in preeclamp sFlt-1 ⬆️ in preeclamp sFlt-1: PlGF ratio is much higher in preeclampsia

#ACR19 @rheumnow abs1339 Risk of ImmunoRx related toxicity in pts w/pre-existing AI disease+ malignancy &Rx w/ ICIs comparable to pts w/out preexist AI Dx: IrAEs 32%pts w/only 9% severe,grade 3 irAEs, total 41% toxicity of any grade. most common tox dermatitis 18%& colitis 14%

#acr19 @rheumnow Great debate Who won? Dr Saag (62% yes votes) But Dr Humphrey NO-anabolic stance as first line for GIO make sense for many patients; antiresorptives do work for GIO and cost per fracture prevented is so much less

#acr19 @rheumnow Great debate Dr Saag rebuttal PRO anabolic 1st line rationale for GIO: - Dr Humphrey herself wrote in 2014 and 2018 that teriparatide can be considered as 1st line for GIO https://t.co/GjMrs0YYdj

For persistent arthritis after checkpoint inhibitor cessation, DMARDs don’t seem to blunt tumor response. Increasing issue given the number of patients on combo therapy at risk of arthritis persistence post-ICI cessation. Congratulations @cappelliMD &Dr Braaten!! #ACR19 @RheumNow https://t.co/C3N13D3Dqm https://t.co/H66bnMGGkL

• Laura Cappelli on Twitter: "So proud of Tawnie Braaten for her hard work i…

Which new therapeutic agent in late stage development are you most excited about using in the future? #ACR19 @RheumNow